Eric Loumeau - Nov 4, 2021 Form 4 Insider Report for ANAPTYSBIO, INC (ANAB)

Role
COO, General Counsel
Signature
/s/ Eric Loumeau
Stock symbol
ANAB
Transactions as of
Nov 4, 2021
Transactions value $
-$89,550
Form type
4
Date filed
11/5/2021, 06:23 PM
Next filing
Nov 17, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ANAB Common Stock Options Exercise $35.1K +2.5K $14.02 2.5K Nov 4, 2021 Direct
transaction ANAB Common Stock Options Exercise $50.4K +2.5K +100% $20.16 5K Nov 4, 2021 Direct
transaction ANAB Common Stock Sale -$175K -5K -100% $35.00 0 Nov 4, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ANAB Employee Stock Option (Right to Buy) Options Exercise $0 -2.5K -2.84% $0.00 85.5K Nov 4, 2021 Common Stock 2.5K $14.02 Direct F2, F3
transaction ANAB Employee Stock Option (Right to Buy) Options Exercise $0 -2.5K -25% $0.00 7.5K Nov 4, 2021 Common Stock 2.5K $20.16 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person.
F2 The stock option vested and is exercisable as to 25% of the shares subject to the option on December 6, 2020, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.
F3 In addition to the remaining options to purchase 93,000 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 137,500 shares of common stock, which options vest according to their terms.
F4 The stock option vested and is exercisable as to 25% of the shares subject to the option on July 15, 2021, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.